Discover our latest insights. 

While our skin needs protection from the sun throughout the year, the increased time spent in the sun during the summer can raise the risk of skin damage and skin cancer.

Here is PHM’s recommended checklist on the best ways to protect yourself from the sun’s damaging UV rays and reduce your risk of developing skin cancer.

Hot flashes are the most common symptom of menopause, occurring in 75% of all women and often persisting for years. For some women, hot flashes are mild, infrequent, and do not require treatment. Others have more intense and frequent hot flashes that negatively affect their quality of life, including sleep interruption, mood changes, difficulty concentrating, and interference with daily activities. Read now for a brief review the existing treatments and a newly approved, non-hormonal treatment option.

For a very long time, the only option for breast cancer treatment was a radical mastectomy. Treatment slowly began to evolve in the 1960s with hormone therapy, radiation, and chemotherapy being adopted into clinical practice. But today, treatment options are evolving much more rapidly.

Cardiovascular diseases, including heart attack and stroke, cause 1 in 3 deaths in women each year¹. Some symptoms that women commonly experience during a heart attack are more subtle than the “classic” male symptoms. As a result, many women may not realize they are having a cardiovascular emergency and fail to seek treatment. Here, PHM share valuable information about heart attack and strokes in women, including new tools that are available for managing your heart health, along with symptoms, prevention, and risk management.

The drugs, Wegovy® and Ozempic® have been in the news and trending on social media due to their unprecedented success in helping people lose large amounts of weight. Our experts at PHM answer some common questions about the recently FDA approved drug, Wegovy.

Leqembi® (lecanemab) was approved to treat Alzheimer’s disease in January, 2023 under the FDA’s Accelerated Approval process for diseases with an unmet need for treatment.1 The manufacturers, Eisai pharmaceuticals, plan to submit data for full FDA approval by the end of March 2023.

Here, we answer some common questions about Leqembi and summarize what is known about its safety and effectiveness. Patients and their families should speak with their physician and weigh the potential benefits and risks before deciding whether to seek treatment with Leqembi.